Authors
Latest:
Immunotherapy Agents in Pancreatic CancerMargaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the potential for immunotherapies in pancreatic cancer.
Latest:
Phase III INVICTUS Trial Evaluates Ripretinib in Advanced GISTMargaret von Mehren, MD, discusses the rationale for evaluating ripretinib in patients with heavily pretreated advanced GIST in the phase III INVICTUS trial, which was presented at the ESMO Congress 2019.
Latest:
Diagnostic Platforms for Lung CancerMaria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses diagnostic platforms for lung cancer.
Latest:
Unmet Needs in Advanced or Metastatic TRK Fusion-Positive Thyroid CancerMarie E. Cabanillas, MD, discusses current unmet needs in advanced or metastatic TRK fusion-positive thyroid cancer.
Latest:
How Mutation Status Affects Individualization of Treatment in mCRCMaria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses how mutation status effects individualization of treatment in metastatic colorectal cancer (mCRC).
Latest:
Advancing Interest in Immune Checkpoint Blockade for GI CancersMaria Svensson, MD, Lund University, discusses the growing interest in checkpoint inhibitor blockade treatments for gastrointestinal cancers. In the past, there have been promising results with this treatment in metastatic disease.
Latest:
Survival Benefit Confirmed in Real-Life Analysis of Second-Line Regorafenib in HCCMaría Varela, MD, PhD, discusses the findings from a real-life analysis to confirm the benefit of regorafenib as treatment of patients with hepatocellular carcinoma who have progressed on prior sorafenib. Regorafenib was approved by the FDA for second-line treatment in this patient population based on data from the phase III RESORCE trial.
Latest:
Key Takeaway Points in Phase III ALCYONE Trial for Multiple Myeloma<br /> ​Maria-Victoria Mateos, MD, PhD, discusses the key takeaways from the findings from the phase III ALCYONE trial for patients with multiple myeloma.
Latest:
Marianne Davies, NP, on Assessing Immunotherapy Toxicities in Lung Cancer PatientsMarianne Davies, NP, discusses making patients' oncology team their first line of contact should they develop any toxicities related to receiving treatment. Davies says this is important for patients so that the oncology team can assess whether it is an immune-related side effect, or an issue that can be dealt with by their primary care physician.
Latest:
Immune Checkpoint Inhibitors Approach Frontline Setting in Head and Neck Squamous Cell CancerImmune checkpoint inhibitors as monotherapy and in combinations regimens are producing promising efficacy data in metastatic head and neck cancers, depite struggles in finding the right treatment settings and patient population subsets.
Latest:
SHP2 Inhibitors Open the Door to Treat KRAS-Mutant CancersAgents that inhibit SHP2 attack cancer cells in a way that is distinct from other therapies, and data showing the potential efficacy of such therapies, are fueling more research.
Latest:
Study Results Show Multidisciplinary Tumor Boards Lead to Improved OS for HCC PatientsMultidisciplinary tumor boards led to higher utilization of guideline-recommended curative therapies, which was associated with improved overall survival (OS) for patients with early-stage hepatocellular carcinoma.
Latest:
PD-L1–High Advanced NSCLC: Future Directions in CareClosing out her discussion on PD-L1–high metastatic NSCLC, Marina Chiara Garassino, MD, looks toward future evolutions in the treatment paradigm.
Latest:
CPI-0610 Demonstrates Activity in Patients With Myelofibrosis After Ruxolitinib FailureMarina Kremyanskaya, MD, PhD, discusses unique findings from the phase II trial investigating the effect of CPI-0610, a bromodomain and extra-terminal protein inhibitor, as treatment for patients with myelofibrosis who previously progressed on ruxolitinib.
Latest:
The Impact on Quality of Life of Dermatologic AEsMario E. Lacouture, MD, dermatologist, Memorial Sloan Kettering Cancer Center, discusses the impact on quality of life of dermatologic adverse events.
Latest:
Clinical Trials Enrolling for Ovarian Cancer at Memorial Sloan Kettering Cancer CenterMario M. Leitao, Jr, MD, FACOG, FACS, program director of Gynecologic Oncology at Memorial Sloan Kettering Cancer Center, highlights some of the phase I and II clinical trials in ovarian cancer currently enrolling at his institution. He also discusses the rationale behind a new trial that is expected to open soon.
Latest:
The Role of High-Dose IL-2 in RCCMario Sznol, MD, professor of medicine, Yale Cancer Center, discusses the role of high-dose IL-2 for the treatment of renal cell carcinoma (RCC).
Latest:
Current Systemic Management of Pleural Malignant MesotheliomaMalignant mesothelioma is an uncommon malignancy of the pleura that is usually associated with asbestos exposure.
Latest:
The Role of Robotic Surgery in Gynecologic CancerMark A. Morgan, MD, discusses the role of robotic surgery in gynecologic cancer.
Latest:
Immunotherapy in GU CancersMark A. Rubin, MD, director, Institute for Precision Medicine, Weill Cornell Medical College, discusses immunotherapy in the field of genitourinary cancers.
Latest:
Ways to Manage Toxicities Related to Osimertinib for Lung CancerMark A. Socinski, MD, discusses his approach to managing toxicities related to osimertinib for patients with non–small cell lung cancer and EGFR mutations.
Latest:
Investigating MET Exon 14 Mutations in Patients With NSCLCMark M. Awad, MD, PhD, discusses the characterization of patients with non–small cell lung cancer who have MET exon 14 skipping alterations and potential acquired resistance mechanisms.
Latest:
Exceptional Responders to Anti-PD1 Therapy in Renal Cell CarcinomaMark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti-PD-1 therapy in renal cell carcinoma.
Latest:
Expert Discusses Practice-Changing Data From KATHERINE Trial in Breast CancerMark D. Pegram, MD, discusses how the results from the phase III KATHERINE trial will change practice for the treatment of patients with breast cancer.
Latest:
Dr. Mark Emberton on the Role of Focal Therapy in Prostate CancerEmberton says that in treatment of most solid tumor cancers, oncologists have moved from treating the whole organ to specifically targeting the tumor.
Latest:
KRAS and Outcomes in Pancreatic CancerMark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.
Latest:
Expert Highlights Key Topics of Discussion at the 15th Annual New York Lung Cancers SymposiumMark G. Kris, MD, discusses 1 of the major topics of discussion from the 15th Annual New York Lung Cancers Symposium, among other areas of focus at the meeting.
Latest:
Dr. Mark Gilbert on Genetics as a Predictive Tool for Treatment Response in Brain CancerMark Gilbert, MD, neuro-oncologist, chief of neuro-oncology, National Institute of Health, discusses predicting how a patient's brain tumor might act and respond to treatment based on their genetics.
Latest:
Key Data From the BMT CTN 1506/MORPHO Trial of Gilteritinib in FLT3-ITD+ AMLMark J. Levis, MD, PhD, discusses the takeaways from the phase 3 BMT CTN 1506/MORPHO trial which evaluated maintenance gilteritinib after allogeneic stem cell transplant in patients with FLT3-ITD–positive acute myeloid leukemia.
